The affordability of medication and health-care treatment is always a major concern for patients with poor economic backgrounds. Particularly in this part of the world, hundreds of thousands of people suffering from various communicable and non-communicable diseases (NCDs) do not have timely access to medicines since they are not able to afford the treatment required. 

In such a depressing scenario, however, there is good news for poor patients as one of the leading pharmaceutical companies has initiated a health-care programme worldwide, including Pakistan, focusing on affordability and availability of commonly prescribed medicines. 

The programme ensures the access to medicines by offering the same at a negligible price of USD 1 per treatment per month, covering the treatment of such common non-communicable diseases (NCDs) as diabetes, breast cancer, respiratory and cardiovascular diseases. 

Since Pakistan is ranked among the low-middle income countries (LMICs), this one-dollar initiative will play a leading role in improving access to quality medicines and healthcare in the country. 

KASHIF MUSTAFA QADRI,  

Karachi, October 2.